U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06851858) titled 'Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist' on Feb. 13.
Brief Summary: This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Study Start Date: Feb. 21
Study Type: INTERVENTIONAL
Condition:
Endocrinology
Diabetes, Type II
Obesity
Intervention:
DRUG: AZD6234
Weekly SC injections of AZD6234
DRUG: Placebo to match
W...